A cute trauma 1 and surgical interventions 2 can, especially when prolonged, induce hemostatic changes that may precipitate severe and lifethreatening hemorrhage. Conventional treatment of coagulopathy and bleeding involves the use of surgical interventions and compression or tamponading, as well as blood component therapy (fresh frozen plasma [FFP] , cryoprecipitate, platelet concentrates, packed red blood cells [PRBC] ) and correction of A retrospective analysis is described to assess the effects of using recombinant activated factor VII to control bleeding in a series of patients who had failed to respond to conventional hemostatic measures. In all, 18 patients (aged 16-65 years) with a range of conditions resulting in bleeding refractory to conventional methods of control were treated with recombinant activated factor VII (60-120 μg/kg; 1-4 doses). The effects of recombinant activated factor VII on bleeding were noted together with the patients' transfusion requirements and hematological parameters. Administration of recombinant activated factor VII successfully stopped bleeding in 17 of the 18 patients. Therapy with recombinant activated factor VII significantly decreased transfusion requirements for packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate compared with pretreatment values along with significant improvement in hemostasis. In various serious bleeding situations, treatment with recombinant activated factor VII may effectively arrest bleeding, which has remained refractory to conventional methods of control. lack preexisting coagulopathies and in whom conventional methods failed to provide adequate control of bleeding. [20] [21] [22] [23] [24] [25] Clinical trials in surgical 2 and trauma patients 26 have subsequently confirmed the therapeutic potential of rFVIIa for bleed management in these patients. The therapeutic potential of rFVIIa in emergency settings is enhanced by its rapid preparation and infusion time and a short halflife (∼2 hours).
The precise mechanism by which rFVIIa promotes hemostasis remains to be definitively established. However, rFVIIa appears to act by promoting a strong stable clot and by enhancing coagulation regardless of any preexisting coagulopathy. 22 It has been proposed that, in the absence of coagulopathy, rFVIIa forms a complex with tissue factor at sites of vessel damage thereby augmenting the tissue-factor dependent hemostatic pathway. 27 Alternatively, and independently of tissue factor, rFVIIa may bind to activated platelets at an injury site, activating factor X and generating a burst of thrombin. 28, 29 The effects of rFVIIa in enhancing hemostasis are localized to the injury site in a time-limited manner thus avoiding systemic activation of the coagulation cascade. 30, 31 We report retrospectively a series of cases in which rFVIIa has been used to affect hemostasis in patients with a range of conditions resulting in bleeding that could not be controlled by conventional measures.
Patients and Methods

Patients
Eighteen patients were included in this case series. The patients were treated between June 2001 and June 2004. They received rFVIIa in an attempt to control bleeding that was associated with a range of causes. The bleeding could not be controlled by conventional measures. Details of the cases are summarized in Table 1 .
Six of the patients underwent surgery that resulted in bleeding arising from various procedures: pseudocyst drainage (patient 7), percutaneous transluminal coronary angioplasty (PTCA; patient 9), laparoscopic adjustable gastric banding (patient 10), ligation of the left internal iliac artery (patient 12), and aortic-bifemoral bypass (patients 14 and 15).
Five patients were treated for trauma, with 3 patients treated for injuries sustained due to road traffic accidents (patients 5, 6, and 16). Patient 5 had a history of Glanzmann thrombasthenia and sustained a pelvic fracture and multiple bruising. A computed tomographic (CT) scan showed right perinephric collection and retroperitoneal hematoma. Patient 13 fractured his left femur and pelvis after falling from a height. Abdominal distension was observed and a laparotomy indicated damage to his mesenteric vessels, which continued to bleed excessively after reparative surgery. Patient 17 sustained a fractured pelvis, retroperitoneal hematoma, and injuries to his bladder and urethra after a heavy object fell onto his pelvis. External fixation of the pelvis and urinary catheterization were performed, but the patient required massive transfusion of blood products.
Three obstetric patients (patients 1-3) experienced severe hemorrhages after Cesarean sections (CSs). Both patients 1 and 2 had placenta previa. An elective CS was performed for patient 1, but patient 2 required emergency surgery because of placenta abruptio. Patient 3 had an elective CS with a subsequent transabdominal hysterectomy performed in an unsuccessful attempt to stop her bleeding.
Three patients had spontaneous bleeding. Patient 8 was diagnosed with immune thrombocytopenic purpura associated with menorrhagia. Hormonal manipulation and other measures failed to control the bleeding, and the patient's platelet level did not respond to therapy with intravenous immunoglobulin or high-dose steroids. Patient 11 had a history of liver cirrhosis and portal hypertension. He had massive hematemesis resulting from bleeding gastric varices, and the coagulopathy was apparent. Patient 18 had ulcerative colitis and rectal bleeding, which could not be controlled by conventional methods.
One of the cases was related to organ transplantation. Patient 4 had undergone a renal biopsy to investigate deteriorating renal function 1 week after a kidney transplant. Continuous and massive hematuria had ensued.
Administration of rFVIIa
There were no predetermined criteria for the administration of rFVIIa. Therapy was given at the discretion of the physician treating the patient after other measures to control bleeding had failed. Blood products given to each patient prior to rFVIIa administration are shown in Table 2 . Table 1 shows the bolus dose of rFVIIa received by each patient. In this column, 0 implies that the bleeding stopped, or the blood loss was so low that it was not measurable, and a dash (-) indicates that data are not available. c Bleeding did not stop and the patient died.
d Fresh blood was no longer being passed from the rectum 6 h after the first dose of rFVIIa.
Data Collection and Analysis
Clinician observations in response to rFVIIa were recorded, with the transfusion requirements for PRBC, platelets, cryoprecipitate, and FFP before and after the administration of rFVIIa. Where appropriate, statistical analyses of these data were performed using the Wilcoxon signed-rank test for paired data.
Predosing and postdosing hematological parameters (prothrombin time [PT], international normalized ratio [INR], activated partial thromboplastin time [aPTT], platelets, and hemoglobin) were also recorded where possible. Statistical analyses of these data were performed using the Wilcoxon signed-rank test for paired data.
Blood pressure and pulse data were recorded for all patients, and pre-rFVIIa and post-rFVIIa treatment data were compared using paired t tests.
All adverse events were recorded until patients were either stable or discharged from hospital.
Results
Outcomes
Bleeding ceased following rFVIIa administration in 17 of the 18 patients (94.4%; Table 2 ). Bleeding stopped within 2 to 36 hours of administration of rFVIIa. Bolus dosing of rFVIIa ranged from a single dose of 60 μg/kg to 4 doses of 120 μg/kg. The number of doses of rFVIIa that patients received depended on their response to the agent, with more rFVIIa given if the bleeding did not stop.
Bleeding was not arrested by rFVIIa in patient 9. This patient had a history of coronary artery disease and pulmonary hypertension. After receiving an emergency PTCA, she collapsed showing signs of hypovolemic shock. A CT scan revealed a large retroperitoneal hematoma. The patient received 5 units of PRBC but continued to show signs of hemodynamic instability, as a result of which rFVIIa was administered. The patient's condition deteriorated, and she died 4 hours after the PTCA. Death was related to the patient's underlying condition and complications arising from the PTCA, not to rFVIIa, which had been administered when the patient's prognosis was already poor.
Transfusion Requirements
The blood loss experienced by the individual patients before and after rFVIIa administration is shown in Table 2 , with their transfusion requirements. As paired data for blood loss were available for only 9 of the 18 patients, the data are biased and cannot be generalized for the whole sample of patients. However, for these 9 patients, the median blood loss before treatment with rFVIIa was 3.0 L compared with a median value of 0.25 L after treatment with the agent (P = .015).
Data relating to transfusion requirements before and after the administration of rFVIIa were available for all 18 patients, and these are summarized in Table 3 . Significant decreases in the requirements for PRBC (P < .001), FFP (P = .001), platelets (P = .002), and cryoprecipitate (P = .011) were evident after the treatment with rFVIIa.
Coagulation Parameters and Other Hematological Data
Coagulation parameters and other hematological data are summarized in Table 4 . Statistically significant decreases in median values for PT (P = .006), INR (P = .001), and aPTT (P = .035) were evident. There were significant increases in the median values for platelet count (P = .025) and hemoglobin concentration (P = .002).
Vital Signs
After treatment with rFVIIa, mean systolic blood pressure increased significantly from 102.7 to 120.1 mm Hg Recombinant Activated Factor VII to Arrest Uncontrolled Bleeding / Alsayegh et al 229 .002 FFP 18 6.5 (0-28) 0 (0-4) <.001 Cryo 18 0 (0-23) 0 (0-6) .011
Note: Cryo = cryoprecipitate; FFP = fresh frozen plasma; PRBC = packed red blood cells; rFVIIa = recombinant activated factor VII. a All values are given as median (range).
(P = .008). Mean diastolic blood pressure increased from 66.6 to 73.2 mm Hg (P = .054). The patients' mean pulse rate decreased from 114.4 to 94.2 (P < .001).
Safety
In all, 1 patient (patient 9) died. This death was not related to the administration of rFVIIa (see above).
No thromboembolic or other adverse events occurred following the administration of rFVIIa in any other patient.
Discussion
We report the use of rFVIIa in 18 patients with bleeding that remained refractory to conventional hemostatic measures. All of the patients we describe experienced severe bleeding (>500 mL of blood loss per hour or hemodynamic instability). The bleeding arose from a variety of causes. In 18 of the 19 patients treated with rFVIIa, hemostasis was achieved. One patient remained hemodynamically unstable after the treatment with rFVIIa and died. The death was not related to rFVIIa.
After the administration of rFVIIa, median blood loss decreased and transfusion requirements for PRBC, platelets, FFP, and cryoprecipitate were statistically significantly reduced. There were also improvements in coagulation parameters.
This case series corroborates the findings of other case reports, which suggest that rFVIIa can provide effective control of bleeding in trauma and surgical patients uncomplicated by severe adverse events. 15, 17, 18, [20] [21] [22] [23] [24] [25] [32] [33] [34] An earlier heterogeneous case series, the largest to date, described a retrospective analysis of 40 surgical and trauma patients who were given rFVIIa when all other measures to stop bleeding had failed. 15 In all, 24 of these patients had undergone cardiac surgery, and 16 had intractable bleeding resulting from a range of other causes (including stab or gunshot wounds, traumatic liver lacerations, and joint replacement). Three of the patients in the latter group had clotting factor abnormalities. Patients surviving for more than 4 hours after rFVIIa administration were evaluated for their response. The 12 surviving patients who had undergone cardiac surgery required significantly fewer transfused units of PRBC, platelets, FFP, and cryoprecipitate after the administration of rFVIIa than before the administration of the agent. The 11 surviving patients who bled for other reasons showed statistically significant decreases in PRBC, platelets, and FFP requirements after treatment with rFVIIa.
Results obtained from the current series and other case studies illustrate the need for guidelines specifying the optimal dosing and timing of administration of rFVIIa for the control of bleeding in trauma and surgical patients. Indeed, guidelines have recently started to appear in the literature. 35, 36 In our study, rFVIIa was used as a last resort in all of the patients. Current knowledge indicates that massive transfusion associated with intractable bleeding increases the risk of life-threatening MOF and infection. Recent clinical trial data 26 indicate that rFVIIa administration prior to the onset of severe coagulopathy is likely to be more effective in reducing both immediate mortality and transfusion requirements. It must be emphasized that we do not recommend the use of rFVIIa as an alternative to conventional hemostatic therapies; adequate replacement therapy before rFVIIa administration is considered to be essential. 18, [24] [25] [26] 37 It would also be advantageous to identify the type of patients who are most likely to benefit from rFVIIa treatment. A recent clinical trial suggests that rFVIIa may be more effective in diffuse bleeding, such as that sustained by blunt trauma, than in hemorrhage caused by penetrating injuries. 26 It can be argued that surgical bleeds, unless resulting from the severing of a major vessel, could be characterized as a diffuse bleed. Although there is concern regarding the potential of rFVIIa to induce thrombosis, previous clinical experience with the agent suggests that it has a good safety profile; to date, the incidence of serious adverse events associated with its use is less than 1%. 38 However, thorough monitoring is recommended in patients with disseminated intravascular coagulation or sepsis. 38 No new safety concerns were identified in the current case series.
In conclusion, we have described the use of rFVIIa in the treatment of 18 patients with severe bleeding that was not arrested by conventional measures. Successful control of bleeding was achieved in 17 of these patients, and no new safety concerns associated with the use of the agent were identified. Randomized controlled clinical trials are required to determine the optimum therapeutic regimen for rFVIIa and to identify the patients who are most likely to benefit from its use.
